Xilio Therapeutics Inc XLO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XLO is a good fit for your portfolio.
News
-
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
-
Thinking about buying stock in RPM International, Xilio Therapeutics, KULR Technology, Torrid Holdings, or IGM Biosciences?
-
Xilio Shares Take Flight Premarket After Gilead Deal
-
Xilio Therapeutics Plans Private Placement, Job Cuts
-
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program
-
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
-
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
-
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Trading Information
- Previous Close Price
- $1.06
- Day Range
- $0.95–1.08
- 52-Week Range
- $0.49–3.40
- Bid/Ask
- $1.01 / $1.04
- Market Cap
- $37.28 Mil
- Volume/Avg
- 239,428 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 0.32
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 73
- Website
- https://www.xiliotx.com
Comparables
Valuation
|
Metric
|
XLO
|
CLDX
|
TYRA
|
|---|---|---|---|
Price/Earnings (Normalized) | 0.32 | — | — |
Price/Book Value | 0.79 | 4.82 | 3.18 |
Price/Sales | — | 260.58 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
XLO
CLDX
TYRA
Financial Strength
|
Metric
|
XLO
|
CLDX
|
TYRA
|
|---|---|---|---|
Quick Ratio | 2.80 | 13.69 | 13.27 |
Current Ratio | 3.02 | 13.87 | 13.80 |
Interest Coverage | −108.15 | — | — |
Quick Ratio
XLO
CLDX
TYRA
Profitability
|
Metric
|
XLO
|
CLDX
|
TYRA
|
|---|---|---|---|
Return on Assets (Normalized) | −71.63% | −30.49% | −22.50% |
Return on Equity (Normalized) | −99.41% | −33.19% | −23.73% |
Return on Invested Capital (Normalized) | −79.65% | −32.85% | −27.79% |
Return on Assets
XLO
CLDX
TYRA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rmqcrbpsx | Bqb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xhhggxht | Spmkvp | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bhcbpwf | Bvprjp | $97.8 Bil | |
MRNA
| Moderna Inc | Vslvxpcym | Dvdr | $38.8 Bil | |
ARGX
| argenx SE ADR | Gwmsnjqw | Yplm | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Tfhhsnrv | Cjtw | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rfgdbzkb | Ztzygzh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kbpdxtzt | Whjwjx | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vpbtxxtn | Kzqhvlw | $12.5 Bil | |
INCY
| Incyte Corp | Jqfgyhbz | Xgvqpxw | $11.5 Bil |